In haemophilia A patients, replacement therapy with factor VIII products has become state of the art. However, a serious complication in the treatment of haemophilia A is the development of neutralizing antibodies against FVIII, causing therapy resistance and increased risk of bleeding.
Go to Source

This entry was posted on Tuesday, July 31st, 2012 at 12:30 pm and is filed under European Medicines Agency. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.